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any treatment was 23 weeks vs. 9 weeks in pts with BSC, 
p<0.0001. In pts who received local treatment (8: surgery + 
3: RT) median PPS was 51 vs. 21 weeks for CHT, p = 0.36. 
Median PPS for surgery was 51 weeks vs. 17 weeks for RT, p = 
0.62. Pts with poor KPS (<60) at relapse did not benefit from 
local treatment as compared with CHT: median PPS for local 
treatment vs. CHT was 14 vs. 18 weeks, p = 0.81. Median PPS 
for poor KPS pts with BSC was 7 weeks. For the whole group 
of 84 pts, median OS from randomization was 35 weeks: 55 
vs. 30 weeks in pts who received any treatment vs. BSC only, 
p < 0.0001. 
 
 
Conclusions: Our results suggest that an active therapeutic 
approach may be beneficial for selected elderly and/or frail 
pts with rGBM, compared to BSC alone. Re-surgery seems to 
be the most efficacious therapeutic option for rGBM in 
elderly pts with high KPS; in poor KPS pts there is no benefit 
of local treatment (surgery and/or RT) over CHT.  
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Purpose/Objective: To report on outcomes and toxicity after 
proton beam radiotherapy for large non-peripapillary 
choroidal melanoma considered unsuitable for other eye-
sparing therapies in Canada. 
Materials and Methods: We included patients with non-
peripapillary tumors (>2mm from the optic disc) treated with 
proton therapy at TRIUMF, the only ocular proton therapy 
facility in Canada, from 1995-2013. A prospective database 
including patient, tumor, and treatment characteristics was 
updated with ocular complications and follow up status from 
chart reviews. 
Results: In total, 77 patients were included in the analysis. 
The median age was 60 years and the median observation 
time 47 months (0-221 months). More than half of the 
patients (53%) had a tumor located anterior to the equator 
and 35% had involvement of the ciliary body. The median 
tumor diameter was 13.6 mm and the median thickness was 
7.1 mm. The 5 -(10) year actuarial rate was 85 (85)% for 
ocular tumor control, 72 (57)% for metastasis-free survival, 
77 (63)% for overall survival, 22 (22)% for enucleation and 38 
(38)% for complete blindness. 80% of patients with blindness 
had developed neovascular glaucoma. 
For patients with good vision (≥20/50) at baseline, the 5-(10) 
year actuarial rate was 40 (40)% for conservation of vision of 
20/50 or better, 44 (44)% for conservation of vision of 20/200 
or better and 67 (67)% for conservation of vision of counting 
fingers or better.  
On univariate analysis, patients with ciliary body involvement 
had significant worse metastasis-free survival and overall 
survival rates compared to patients without ciliary body 
involvement (p<0.001). 
Conclusions: Proton therapy resulted in acceptable local 
control and survival rates in patients with large anteriorly 
located tumors. The risk of complete blindness and severe 
toxicity requiring enucleation was low and a substantial 
proportion maintained a useful vision.  
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Purpose/Objective: * RECTAL BOOST = RandomizEd 
Controlled Trial for pre-operAtive dose-escaLation BOOST in 
locally advanced rectal cancer. 
Randomized controlled trials (RCTs) are the gold standard to 
evaluate effectiveness of new interventions. RCTs often 
experience difficulties in recruitment and generalizability. 
We introduced the 'cohort multiple Randomized Controlled 
Trial' (cmRCT) to efficiently and simultaneously evaluate 
multiple oncologic of interventions, while maintaining the 
highest level of evidence. 
The RECTAL BOOST* study, which compares response rates 
after boost plus standard chemoradiation (CRT) (intervention 
arm) to standard chemoradiation alone (control arm) in 
patients with locally advanced rectal cancer (LARC), is the 
first clinical study according to cmRCT design. We evaluated 
feasibility of this design in terms of recruitment rates and 
boost-offer acceptance. 
Materials and Methods: The basis of this 'cohort multiple 
Randomized Controlled Trial' (cmRCT) is a cohort consisting 
of all patients with rectal cancer. Patients consent to 
prospective collection of clinical, histological and quality-of-
